Volume 11, Number 8—August 2005
Dispatch
Cost-Benefit of Stockpiling Drugs for Influenza Pandemic
Ran D. Balicer*†
, Michael Huerta*, Nadav Davidovitch*†, and Itamar Grotto*†
, Michael Huerta*, Nadav Davidovitch*†, and Itamar Grotto*†
Table A4
Preexposure (seasonal) prophylaxis trials included in the analysis
| Trial | Age group, y | Intervention (no. participants) | Treatment duration |
|---|---|---|---|
| Hayden et al., 1999 (11) | 18–65 | Oseltamivir 75 mg 1×/d (520) | 6 weeks |
| Oseltamivir 75 mg 2×/d (520) | |||
| Placebo (519) | |||
| Monto et al., 1999 (15) | 18–69 | Zanamivir 10 mg 1×/d (553) | 4 weeks |
| Placebo (554) |
Page created: April 23, 2012
Page updated: April 23, 2012
Page reviewed: April 23, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.